YEKATERINA ZHUPAN: Open Payments
NPI 1548905425 · NEW YORK, NY. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$2,471 in 106 payments from 28 companies in 2025. Trend: 2023 $669 · 2024 $954 · 2025 $2,471
Food & beverage: $2,163Education: $309
| Company | Payments | Amount |
|---|---|---|
| Janssen Biotech, Inc. | 16 | $426 |
| Novartis Pharmaceuticals Corporation | 24 | $375 |
| E.R. Squibb & Sons, L.L.C. | 9 | $204 |
| Gilead Sciences, Inc. | 5 | $188 |
| BeOne Medicines USA, Inc. | 5 | $126 |
| AstraZeneca Pharmaceuticals LP | 5 | $120 |
| Incyte Corporation | 2 | $119 |
| PFIZER INC. | 4 | $113 |
| SOBI, INC | 4 | $89 |
| GlaxoSmithKline, LLC. | 3 | $80 |
Products named: Trodelvy, BRUKINSA, Fabhalta, RYBREVANT, REBLOZYL, LUTATHERA, IBRANCE, DARZALEX.
Industry payments across NY — which companies pay providers there.
